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The neuregulins (NRGs) represent a large family of membrane-anchored
growth factors, whose deregulation may contribute to the pathogenesis of
several tumors. In fact, targeting of NRG-activated pathways has demon-
strated clinical benefit. To improve the efficacy of anti-NRG therapies, it is
essential to gain insights into the regions of NRGs that favor their pro-
oncogenic properties. Here, we have addressed the protumorigenic impact
of different NRG domains. To do this, deletion mutants affecting different
NRG domains were expressed in 293 and MCF7 cells. Of the five forms
studied, only the wild-type and a mutant lacking the Ig-like domain
(NRGDIg) were properly sorted to the plasma membrane. Both forms were
released as soluble forms to the culture media. However, the mutant
NRGDIg failed to efficiently activate HER2 and HER3 receptors, signaling
pathways, and cell proliferation when compared to wild-type NRG. Treat-
ment with trastuzumab, a humanized antibody used in the breast cancer
clinic, inhibited the constitutive activation of HER2, HER3, and down-
stream signaling in MCF7 cells constitutively expressing wild-type NRG.
In contrast, this treatment had a marginal effect on MCF7-NRGDIg cells.
This study demonstrates that the Ig-like region of NRGs exerts an impor-
tant role in their capability to activate ErbB/HER receptors and mitogenic
responses. Strategies aimed at targeting NRGs should consider that fact to
improve neutralization of the pro-oncogenic properties of NRGs.
1. Introduction
The neuregulins (NRGs) are a group of polypeptide
growth factors of the epidermal growth factor (EGF)
family which participate in various physiological pro-
cesses such as heart and peripheral nervous system devel-
opment (Breuleux, 2007; Britsch et al., 1998; Falls, 2003;
Massague and Pandiella, 1993; Meyer and Birchmeier,
1995; Montero et al., 2008). The NRGs act by binding to
the extracellular region of the ErbB/HER transmem-
brane tyrosine kinases, particularly HER3 and HER4
(Burden and Yarden, 1997; Carraway and Burden,
1995). Upon binding of NRGs to their extracellular
region, the receptors dimerize, especially with HER2
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(Burden and Yarden, 1997; Carraway and Burden, 1995;
Jeong et al., 2014), and this leads to activation of a com-
plex network of downstream signaling events (Esparis-
Ogando et al., 2016).
Four different NRG genes code for more than 30 dif-
ferent isoforms, most of them synthesized as membrane-
bound forms, generically termed proNRGs (Falls, 2003;
Hayes et al., 2007; Montero et al., 2008). Because of
their transmembrane disposition, the proNRGs are con-
stituted by three blocks: the N-terminal extracellular
domain, the transmembrane domain, and the C-term-
inal intracellular region. The N-terminal extracellular
block includes the EGF-like module, together with
other regions such as Ig-like or the kringle-like subdo-
mains (Falls, 2003; Wen et al., 1994). The EGF-like
domain is critical for HER receptor binding and activa-
tion (Holmes et al., 1992; Wen et al., 1994), while the
Ig-like domain appears to favor interaction with extra-
cellular matrix components (Loeb and Fischbach, 1995;
Loeb et al., 1999). The role of the Ig-like domain in reg-
ulating the interaction of NRGs with their receptors is
controversial. In fact, while some studies have indicated
that the Ig-like region may promote the interaction of
soluble NRGs with their receptors, favoring activation
of the latter (Eto et al., 2006), other studies suggested
that such domain conferred signal attenuation by induc-
ing downregulation of ErbB/HER receptors (Warren
et al., 2006). The ectodomain of the proNRGs is con-
nected to an internal hydrophobic domain that acts as
both a transmembrane domain and a signal sequence
(Falls, 2003). That transmembrane region is followed by
an intracellular domain which varies in length among
the different NRG isoforms, but appears to be required
for the adequate sorting of proNRGs to the plasma
membrane (Montero et al., 2011).
The membrane-bound proNRG forms may undergo
proteolytic processing to generate soluble forms of the
factor (Falls, 2003; Montero et al., 2000). Such process
is slow under resting conditions, but may accelerate
under situations in which intracellular signaling path-
ways are stimulated (Montero et al., 2000, 2002). In
fact, activation of routes that increase phosphorylation
of cellular proteins provokes ectodomain cleavage of
proNRGs, generating soluble NRGs (Montero et al.,
2000, 2002). Such proteolytic event is accomplished by
membrane metalloproteases of the ADAM subfamily,
especially by ADAM17 (also termed TACE) or
ADAM10 (Ebbing et al., 2016; Montero et al., 2000).
Deregulation of NRGs has been linked to important
pathological processes such as cancer or schizophrenia
(Breuleux, 2007; Mei and Xiong, 2008; Montero et al.,
2008). In fact, several studies suggested that NRGs play
a role in the genesis or progression of breast tumors.
Thus, expression of NRGs in the mammary gland of
mice provoked the appearance of breast adenocarcino-
mas (Krane and Leder, 1996). Moreover, increased
expression of NRGs has been described in up to 50%
of human breast tumors, and such increased expression
has been linked to poor patient outcome (de Alava
et al., 2007). That negative impact on the clinical evolu-
tion of patients bearing NRG+ tumors may be related
to the pro-oncogenic properties of NRGs, which
include promotion of cell proliferation, migration, or
metastatic dissemination (Atlas et al., 2003; Seoane
et al., 2016; Tsai et al., 2003; Yuste et al., 2005). More-
over, some reports have linked NRG expression to the
effectiveness of certain antitumoral therapeutics (de
Alava et al., 2007). Thus, NRG expression in breast
tumors has been shown to biomark sensitivity to the
anti-HER2 therapeutic antibody trastuzumab (Meetze
et al., 2015). In addition, NRGs may provoke resis-
tance to certain therapies used to target HER2 (Sch-
warz et al., 2017; Yang et al., 2017).
Those evidences raise the possibility that NRG target-
ing may be therapeutically useful in situations in which
NRGs play a pro-oncogenic role favoring tumor growth
or dissemination. In fact, and in addition to the above-
mentioned evidences obtained in breast cancer, a recent
report has demonstrated the clinical value of targeting
NRG–HER system in patients with tumors containing
NRG1 gene rearrangements (Jones et al., 2017; Kim
et al., 2016). Interestingly, some of these rearrange-
ments excluded parts of the N-terminal region of
NRG1-derived gene products whose biological function
(s) are still poorly known (Eto et al., 2006; Kim et al.,
2016). Reasonably, a better knowledge of the biological
properties of the different proNRG domains may help
in designing adequate anti-NRG strategies. Considering
this, and to gain additional insights into the relevance of
different proNRG domains in their biological action,
we prepared several deletion mutants and explored their
role in regulating proNRG signaling. We show that
elimination of the Ig-like domain of proNRGs strongly
affected the HER receptor activating properties of sol-
uble and membrane-anchored proNRGs, which trans-
lated into poor biological activity of NRG forms that
lack the Ig-like region.
2. Materials and methods
2.1. Reagents and immunochemicals
Culture media, fetal bovine serum, trypsin, penicillin,
and streptomycin were from GIBCO BRL (Gaithers-
burg, MD, USA). Protein A-Sepharose, proteinase K,
phorbol 12-myristate 13-acetate (PMA), doxycycline,
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40,6-diamidino-2-phenylindole (DAPI), and 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide
(MTT) were from Sigma-Aldrich (St Louis, MO,
USA). Immobilon-P (PVDF) transfer membrane,
Immobilon-FL membranes, and Amicon Ultra Cen-
trifugal Filters were from Merck Millipore Corp.
(Darmstadt, Germany). Human recombinant neureg-
ulin-1 was from ProSpec Protein Specialists (Rehovot,
Israel). Other generic chemicals were purchased from
Sigma-Aldrich, Roche Biochemicals (Barcelona,
Spain), or Merck (Darmstadt, Germany).
The rabbit anti-NRG endodomain and ectodomain
antibodies as well as the anti-HER3 and anti-HER4
antibodies have been formerly described (Montero
et al., 2000, 2007; Sanchez-Martin and Pandiella, 2012).
Trastuzumab and pertuzumab were purchased from a
local pharmacy. The rabbit polyclonal antibodies to
phospho-HER2 (Tyr1221/1222), AKT, phospho-
MEK1/2 (Ser217/221), MEK1/2, phospho-S6 ribosomal
protein (Ser240/244), phospho-NDRG1 (Thr346), and
phospho-GSK3-a/b (Ser 21/9) and the rabbit mono-
clonal antibodies to phospho-HER3 (Tyr1289) and S6
ribosomal protein were obtained from Cell Signaling
Technologies (Beverly, MA, USA). The mouse mono-
clonal anti-phospho-ERK1/2 (Tyr204), anti-glyceralde-
hyde-3-phosphate dehydrogenase (GAPDH), anti-
phospho-tyrosine (PY99) and the rabbit polyclonal
anti-ERK1/2 antibodies were from Santa Cruz Biotech-
nology (Santa Cruz, CA, USA). The mouse monoclonal
anti-HER2 (clone Ab-3) was from Calbiochem-Behring
Corp. (San Diego, CA, USA). The mouse monoclonal
anti-phospho-AKT (Ser473) was from BD Pharmingen
(Palo Alto, CA, USA). The rabbit polyclonal anti-cal-
nexin was from Stressgen Bioreagents (Victoria, BC,
Canada). The secondary horseradish peroxidase (HRP)-
conjugated antibodies, anti-rabbit, anti-rabbit light
chain, anti-rabbit conformation-specific, and anti-
mouse, were from Bio-Rad Laboratories (Hercules, CA,
USA), Jackson ImmunoResearch Laboratories (West
Grove, PA, USA), Cell Signaling Technologies, and GE
Healthcare Life Sciences (Piscataway, NJ, USA). The
Cy3-conjugated secondary antibody was from Jackson
ImmunoResearch (West Grove, PA, USA). The anti-
mouse DyLightTM 680-conjugated and anti-rabbit
DyLightTM 800-conjugated antibodies were from
Thermo Fisher Scientific (Waltham, MA, USA).
2.2. Cell culture and transfections
MCF7 and 293 cells were grown in Dulbecco’s modi-
fied Eagle’s medium (DMEM) supplemented with 10%
fetal bovine serum (FBS), containing high glucose
(4500 mgL1) and antibiotics (penicillin 100 UmL1,
streptomycin 100 mgmL1). Cell lines were cultured
at 37°C in a humidified atmosphere in the presence of
5% CO2 and 95% air.
The plasmids coding for rat proNRGa2c and the
proNRGDIg, proNRGDintra, proNRGDextra, and NRGb3
mutants were transfected into 293 or MCF7 cells by cal-
cium phosphate or using Lipofectamine (Invitrogen,
Life Technologies, Carlsbad, CA, USA), respectively.
Clones expressing these constructions were selected by
G418 resistance and their NRG expression analyzed by
western blotting (Montero et al., 2000, 2007, 2011).
2.3. Protein extraction, immunoprecipitation, and
western blotting
Detailed procedures for the extraction, quantitation,
and immunoprecipitation of proteins and western blot-
ting can be consulted in Montero et al. (2011).
2.4. Production of soluble NRG
293 and MCF7 cells expressing the wild-type proNR-
Ga2c and the different mutants were plated in 100-mm
dishes and cultured in DMEM with 10% FBS up to
80% confluency. The medium of the cells was replaced
with DMEM without FBS and incubated for 30 min.
This process was repeated three times. Then, cells were
incubated with 5 mL of DMEM without FBS for 24 h.
Conditioned medium was 109 concentrated by ultrafil-
tration using Amicon 3K Ultra Centrifugal Filters
(Merck Millipore Corp.).
2.5. Proteinase protection experiments
293 and MCF7 cells expressing the proNRGa2c or
proNRGDIg were washed once with Krebs/Ringer/
Hepes buffer (containing, in mmolL1: NaCl, 140;
KCl, 5; CaCl2, 2; MgSO4, 1.2; KH2PO4, 1.2; glucose,
6; and Hepes, 25, pH 7.4) and then incubated in this
buffer supplemented with 200 lgmL1 proteinase K
for 30 min at room temperature. Cells were then
washed three times with PBS containing 2 mM PMSF
and lysed in 1 mL of lysis buffer with protease and
phosphatase inhibitors.
2.6. Bioactivity assays
The conditioned media of 293 cells expressing
proNRGs were used to stimulate monolayers of
MCF7 cells for 15 min. On the other hand, clones of
MCF7tetoff expressing proNRGa2c and proNRGDIg
were cultured in DMEM with 10% FBS for up to
40% confluency, after the cells were serum-starved and
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treated with or without doxycycline (10 ngmL1) for
48 h. MCF7tetoff cells expressing proNRGa2c and
proNRGDIg were plated in 24-well plates to a density
of 15 000 cells/well and cultured overnight in DMEM
with 10% FBS. The next day, cells were treated with
or without 10 ngmL1 doxycycline for 48 h. Later,
cells were serum-starved and maintained with or with-
out doxycycline (10 ngmL1) and treated with or
without NRG-1 human recombinant (10 nM). After
5 days, the MTT uptake assay was performed
(Esparis-Ogando et al., 2002). MCF7 cells were plated
in 24-well plates to a density of 15 000 cells/well and
cultured overnight in DMEM + 10% FBS. The next
day, the medium was replaced with DMEM without
FBS containing conditioned media of 293, 293-
NRGa2c, and 293-NRGDIg cells. Cell proliferation
was analyzed at 5 days by an MTT-based assay
(Esparis-Ogando et al., 2002). On the other hand,
clones of MCF7tetoff expressing proNRGa2c and
proNRGDIg were plated in 6-well plates to a density of
30 000 cells/well and were cultured in DMEM with
10% FBS with or without doxycycline (10 ngmL1)
for 48 h. Later, the medium was replaced by DMEM
with 1% FBS and treated with or without doxycycline
(10 ngmL1) and trastuzumab (10 nM) for 5 days. At
the end of incubation, the cells were counted in Z1TM
Coulter Particle Counter (Beckman CoulterTM Life
Sciences, Indianapolis, IN, USA).
2.7. Immunofluorescence
The immunofluorescence protocol has been described
(Esparis-Ogando et al., 2002). Dilutions of the anti-
NRG endodomain or ectodomain antibodies were
1 : 500.
2.8. Quantitative and statistical analyses
Quantitation of the bands obtained from western blot-
ting experiments was performed using the IMAGEJ 1.44
software (National Institutes of Health, Bethesda,
MD, USA) or the ODYSSEY INFRARED IMAGING SYSTEM
V.3.0 (LI-COR, Lincoln, NE, USA). The intensity of
each of the different bands was calculated with respect
to the control, and the data are represented as the per-
centage of the maximum value obtained for each
experiment.
Results obtained in the proliferation experiments are
represented as the mean  standard deviation (SD) of
triplicates of a representative experiment that was
repeated at least three times using IBM SPSS STATISTICS
24 (Madrid, Spain), and differences were tested for sig-
nificance using Student’s t-test. Significance was con-
sidered when P values were < 0.05.
3. Results
3.1. Impact of different proNRG domains on the
production of soluble NRG
To explore the relevance of different domains of
proNRGs in their biological action, distinct deletion
mutants of the isoform proNRGa2c, derived from the
NRG1 gene, were prepared (Fig. 1A). Such isoform was
chosen as it has been extensively used to analyze biologi-
cal characteristics of proNRGs (Montero et al., 2007,
2011). The proNRGa2c mutants constructed included
deletions in (a) the Ig-like domain (proNRGDIg), (b) the
ectodomain (proNRGDextra), (c) the endodomain
(proNRGDintra), and (d) the transmembrane and intra-
cellular domains, generating a form that mimics
NRGb3. Wild-type proNRGa2c and the different
mutants were transfected into 293 cells, and their
expression was evaluated by western blotting. In cell
lysates, and using an antibody raised to the NRG/EGF-
like region of the ectodomain, that antibody recognized
wild-type proNRGa2c, proNRGDIg, proNRGDintra, and
NRGb3 (Fig. 1B, top panel). The antibody failed to rec-
ognize the proNRGDextra form that lacks the extracellu-
lar region. Expression of proNRGDextra form was
Fig. 1. Subcellular localization of NRGa2c and different mutants. (A) Schematic representation of domains of proNRGa2c and distinct
deletion mutants of the isoform wild-type. (B, C) Expression of proNRGa2c and different mutants in 293 cells. 293 cells expressing these
proteins were lysed, and the expression of NRG analyzed by western blotting using the antibody that recognizes the intracellular domain
(anti-NRG endo) (C) or extracellular domain (anti-NRG ecto) (B, top panel). The conditioned medium of these cells was collected, and the
expression of sNRG was analyzed by western blotting using the anti-NRG ecto (B, bottom panel). (D) Immunofluorescence analysis of the
subcellular distribution of proNRGa2c and the different mutants in 293 cells. The localization of proNRGa2c, proNRGDIg, and proNRGDextra
was assessed with the anti-NRG endo antibody and the distribution of proNRGDintra and NRGb3 was analyzed with the anti-NRG ecto
antibody as described in Materials and methods. Images were captured using a Leica TCS SP5 confocal microscope (Barcelona, Spain). Bar,
25 lm. (E) Protease protection experiments of the 293-NRGa2c and 293-NRGDIg cells. These cells were treated with or without proteinase
K (200 lgmL1) for 30 min, and the expression of NRG was analyzed by western blotting using anti-NRG endo antibody. (F) Effect of PMA
in the cleavage of proNRG. 293-NRGa2c and 293-NRGDIg cells were treated with PMA at the indicated times. The expression of NRG in
cells extract (top panel) or conditioned medium (bottom panel) was analyzed by western blotting with the specified antibodies.
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detected using an antibody that recognizes the intracel-
lular region of proNRGa2c (Fig. 1C).
To assess the production of soluble forms of NRGs
(sNRG), culture media were harvested and concen-
trated and NRG analyzed by western blotting using
the anti-NRG ectodomain antibody. These experi-
ments demonstrated that proNRGa2c and proNRGDIg
were able to release soluble forms to the culture media
(Fig. 1B, bottom panel). The molecular weights of the
two soluble forms differed because of the deletion of
the Ig-like region in sNRGDIg. Soluble NRG forms
derived from proNRGDintra or from NRGb3 were
undetectable in the culture media. As expected, soluble
NRG was not detected in the proNRGDextra as this
mutant lacks the NRG/EGF-like domain that contains
the epitope recognized by the antibody.
3.2. proNRGa2c and proNRGDIg are properly
sorted to the plasma membrane and processed
The different capability of 293 cells expressing the dis-
tinct NRG forms to generate soluble forms of NRGs
led us to explore the reason for such differences.
Immunofluorescence studies indicated that the failure
of cells expressing proNRGDintra or NRGb3 to release
sNRG to their culture media was likely due to their
entrapment in intracellular compartments (Fig. 1D).
ProNRGDintra accumulated in a perinuclear intracellu-
lar region, while NRGb3 colocalized with the nuclear
stain DAPI, in agreement with previously reported
results. ProNRGDextra also accumulated intracellularly,
especially in a perinuclear region. The lack of cell sur-
face staining in the case of proNRGDextra and
proNRGDintra confirms that these domains are
required for transport of proNRGs to the plasma
membrane (Montero et al., 2011).
These immunofluorescence studies showed cell sur-
face staining of proNRGa2c and proNRGDIg, suggest-
ing that proNRGDIg reached the cell surface as well as
wild-type proNRGa2c. To verify that proNRGDIg
reached the plasma membrane correctly, protease pro-
tection experiments were carried out. 293-NRGa2c
and 293-NRGDIg cells were treated with proteinase K,
and then, cell extracts were analyzed by western blot-
ting using the anti-endodomain antibody. As shown in
Fig. 1E, treatment of intact cells with proteinase K
caused a profound decrease in transmembrane, cell-
bound proNRGa2c. That effect was accompanied by
the concomitant generation of fragments with molecu-
lar weights of  25 kDa. The latter represent cell-
bound truncated fragments of proNRGs which include
the transmembrane and cytosolic domains. In the case
of 293-NRGDIg cells, the slow-migrating mature form
was sensitive to treatment with proteinase K, and
treatment with the protease resulted in generation of
the 25-kDa tail fragments. The above results indicate
that the presence of the immunoglobulin domain is
not essential for proNRGs to be transported to the
cell membrane.
We also analyzed the relevance of the Ig-like
domain on the cleavage of transmembrane
proNRGDIg. Regulated cleavage of membrane-
anchored growth factors may occur by activation of
several signaling pathways, including the protein
kinase C (PKC) route (Montero et al., 2002). Treat-
ment with the PKC activator PMA caused a decrease
in cell-associated NRG and a concomitant increase in
membrane-associated tail fragments in both 293-
NRGa2c cells and 293-NRGDIg cells (Fig. 1F). Parallel
analyses of culture media showed accumulation of sol-
uble NRGa2c and NRGDIg in cells treated with PMA.
3.3. The Ig-like domain of NRGs facilitates
activation of HER receptors
The HER-activating capability of the culture media
from cells expressing the different NRG forms was
then evaluated. For these experiments, 293 cells were
cultured for 24 h in their growth media, which was
then harvested and after concentration was added to
Fig. 2. Effect of soluble NRG on activation of HER receptors. (A) Schematic representation of bioactivity assay of the soluble NRG. The
conditioned medium of the 293 cells expressing NRGa2c and NRGDIg was collected and concentrated. The levels of NRG in cell extracts or
released into the medium were detected by western blotting. This conditioned medium was used for stimulated the MCF7 cells. (B) Effect of
conditioned medium on activation of HER receptors. MCF7 cells stimulated with the conditioned medium of 293 cells expressing the NRGa2c
and different mutants for 15 min were lysed. One milligram of extract was used to immunoprecipitated HER2 and HER3 and their tyrosine
phosphorylation and total levels were detected by western blotting. The conditioned medium of 293 cells was used as a negative control. (C)
Bar graph representing the quantification of HER2 and HER3 phosphorylation in MCF7 cells stimulated with the conditioned medium of the 293
cells expressing different mutants of NRG. Data are presented as the mean  SD of three independent experiments performed as in (B). (D)
The levels of sNRG released into the medium of 293-NRGa2c and 293-NRGDIg cells were analyzed by western blotting using anti-NRG
ectodomain. The volume of conditioned medium load in the gel is equivalent to the amount in micrograms of cellular extracts (indicated in the
bottom of panel). (E) HER2 and HER3 phosphorylation in MCF7 cells stimulated with the conditioned medium of 293-NRGa2c and 293-NRGDIg
cells. The phosphorylation of HER2 and HER3 in tyrosine-specific residues was evaluated by western blotting using phosphospecific antibodies.
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monolayers of MCF7 cells (Fig. 2A). MCF7 cells
express the NRG receptors HER3 and HER4 which
may oligomerize with other HER receptors, especially
HER2, facilitating transphosphorylation of HER3,
HER4, and HER2. This binary cellular system has
been used to explore paracrine signaling by soluble
NRGs. Media derived from 293 cells expressing wild-
type proNRGa2c caused phosphorylation of HER2
A
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and HER3 (Fig. 2B). Quantitative analyses indicated
higher tyrosine phosphorylation of HER3 receptors as
compared to HER2 receptors (Fig. 2C). Phosphoryla-
tion of HER4 was difficult to detect due to the low
level of expression of this receptor in MCF7 cells (data
not shown). Media harvested from cells expressing the
proNRGDIg were much less efficient in their capability
to induce HER2 and HER3 phosphorylation (Fig. 2B,
C). Media recovered from proNRGDintra or from
NRGb3 cells failed to activate HER2 or HER3
(Fig. 2B,C), in line with the failure to detect sNRG in
the culture media harvested from 293 cells transfected
with these mutants (Fig. 1B). Titration experiments
demonstrated that the lower HER receptor tyrosine
phosphorylation efficiency of conditioned media from
cells expressing proNRGDIg was not due to lower
amounts of sNRGDIg being collected from the culture
media (Fig. 2D).
As these western blotting experiments were per-
formed with a generic anti-pY antibody, the possibility
that the pY signal detected in the western blots was
not exclusively due to HER2 or HER3 in their respec-
tive immunoprecipitates was contemplated. In fact,
coprecipitation of HER2 and HER3 has been reported
in MCF7 cells, particularly when treated with NRG
(Sanchez-Martin and Pandiella, 2012). To explore the
effect of the conditioned media from 293 cells express-
ing proNRGa2c and proNRGDIg on pHER2 and
pHER3, lysates from MCF7 cells incubated with con-
ditioned media harvested from both cell lines were
analyzed by western blotting using antibodies specific
for phosphotyrosine residues present in HER2 or
HER3. As shown in Fig. 2E, immunoprecipitation
with anti-HER2, followed by western blotting with
antibodies that recognize pY1221–1222, pY1139, or
pY877 in HER2, gave weak tyrosine phosphorylation
signals. A much higher signal was observed when
HER3 was immunoprecipitated and western blots were
probed with an anti-pHER3 pY1289 antibody.
Together, these results indicate that soluble NRGs
derived from the conditioned media of cells expressing
proNRGa2c or proNRGDIg principally upregulate tyr-
osine phosphorylation of HER3 in MCF7 cells.
3.4. Signaling responses to soluble NRGa2c and
NRGDIg
Considering the differences found in the tyrosine phos-
phorylation of HER2 and HER3 by sNRGa2c or
sNRGDIg, how the presence of the Ig-like domain
could influence signaling by these receptors was ana-
lyzed. For these experiments, clones of cells expressing
similar protein levels in their transmembrane form and
which released similar amounts of sNRGa2c or
sNRGDIg were selected (Fig. 3A). Time-course experi-
ments were performed to obtain information about the
incubation times to reach maximum HER receptor
activation. These studies showed that tyrosine phos-
phorylation of HER2 receptors caused by conditioned
media containing sNRGa2c or sNRGDIg followed
analogous time courses (Fig. 3B,C), even though
HER2 phosphorylation in response to addition of
sNRGDIg conditioned media was lower than that of
wild-type NRGa2c (Fig. 3B,C). Maximum HER2
phosphorylation was reached within 15 min of incuba-
tion with the conditioned media.
To explore whether the differential activation of HER
receptors by sNRGa2c and sNRGDIg translated into
differences in signaling, MCF7 cells were incubated for
15 min with the concentrated medium collected from
293 cells transfected with proNRGa2c and proNRGDIg.
The levels of expression and phosphorylation of HER2
and HER3 receptors and proteins that serve as readouts
of pathway activation were analyzed (Fig. 3D). These
studies confirmed that the phosphorylation of HER2
and HER3 by conditioned media from 293 cells express-
ing proNRGa2c was much more potent than their acti-
vation by conditioned media from cells expressing
proNRGDIg. Analyses of proteins that act in HER sig-
naling demonstrated that the presence of the Ig-like
domain favored the signaling activity of sNRG. All
evaluated proteins were activated by both forms of
sNRG, but had a higher phosphorylation after incuba-
tion with the medium from 293-NRGa2c cells as com-
pared to the medium from 293-NRGDIg cells.
3.5. Biological activity of proNRGa2c and
proNRGDIg
The effect of NRGa2c or NRGDIg on cell proliferation
was investigated using different experimental settings
aimed at exploring paracrine, juxtacrine and autocrine
modes of intercellular communication (Fig. 4A). The
paracrine model consisted in the addition to MCF7
cells of conditioned media from 293 cells expressing
proNRGa2c or proNRGDIg. The negative control for
these experiments was conditioned medium from 293
cells that do not express NRGs. As shown in Fig. 4B,
conditioned media from 293 cells expressing proNR-
Ga2c provoked an increase in the proliferation of
MCF7 cells, measured using MTT metabolization
assays. In contrast, MCF7 cells incubated with condi-
tioned media from 293 cells expressing proNRGDIg
grew much less, with their MTT values slightly higher
than those of MCF7 cells incubated with the media
from parental 293 cells. These results indicate that the
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paracrine action of sNRGa2c in terms of stimulation
of cell proliferation is superior to that of sNRGDIg.
The second model used consisted in MCF7 cells
expressing proNRGa2c or proNRGDIg. Such model
consists of a single cell type that produces the trans-
membrane growth factor as well as the whole machin-
ery for the transduction of proliferative signals. It
therefore allows the assessment of autocrine/paracrine
as well as juxtacrine properties of proNRGs (Fig. 4A).
For these experiments, MCF7tetoff cells were trans-
fected with the cDNA coding for wild-type proNR-
Ga2c or proNRGDIg, subcloned into the pRevTRE
mammalian expression vector. This system allows the
regulated expression of proteins under the control the
tetracycline transactivator. Several clones of MCF7-
NRGa2c and MCF7-NRGDIg cells were isolated, and
Fig. 4C shows the level of expression of proNRGa2c
and proNRGDIg and their repression by doxycycline in
two clones selected for their analogous expression of
both proNRGs. These clones released similar amounts
of sNRGa2c or sNRGDIg to the culture media
(Fig. 4D). Immunofluorescence experiments showed
that proNRGa2c and proNRGDIg were located at the
plasma membrane of MCF7 cells (Fig. 4E) and colo-
calized with HER2 and HER3 (data not shown). Like-
wise, when the MCF7-NRGa2c and MCF7-NRGDIg
cells were incubated with proteinase K, the slowest
mobility band of each form, which represents the
mature cell surface-exposed proNRG, was proteolyti-
cally processed (Fig. 4F), and this was accompanied
by an increase in the amount of the cell-bound trun-
cated tail fragments. These results are similar to those
obtained in 293 cells (Fig. 1) and demonstrate that
wild-type proNRGa2c and proNRGDIg reach the
plasma membrane and are cleaved to generate soluble
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Fig. 3. Relevance of the Ig-like domain in
the signaling of HER receptors. (A)
Expression of the NRG in cell extract (top
panel) and conditioned medium (bottom
panel) of the 293, 293-NRGa2c, and 293-
NRGDIg cells analyzed by western blotting.
(B) Time course of the effect of
conditioned medium of 293-NRGa2c and
293-NRGDIg cells on HER2
phosphorylation in MCF7 cells. The
conditioned medium of 293 cells was
used as a negative control. (C)
Quantification of HER2 phosphorylation in
MCF7 cells stimulated with conditioned
medium of 293-NRGa2c and 293-NRGDIg
cells. Data were relativized to maximal
phosphorylation obtained and are
represented as the mean  SD of two
independent experiments performed as in
(B). (D) Effect of conditioned medium of
293-NRGa2c and 293-NRGDIg cells in the
signaling of HER receptors. HER2 and
HER3 phosphorylation and the activation
of proteins in HER signaling pathway
were evaluated by western blotting with
the antibodies indicated in the left side of
figure.
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Expression of wild-type proNRGa2c favored prolifer-
ation of MCF7-NRGa2c cells, and such effect was sen-
sitive to doxycycline (Fig. 4G). Proliferation of MCF7-
NRGa2c cells treated with doxycycline was similar to
that of parental, untransfected MCF7 cells. MCF7-
NRGDIg proliferated less than MCF7-NRGa2c cells,
and that proliferation was insensitive to addition of
doxycycline. MCF7-NRGa2c and MCF7-NRGDIg pro-
liferated similarly in response to addition of exogenous



















































































































Fig. 4. Biological activity of NRGa2c and NRGDIg. (A) Representation of the paracrine and juxtacrine/autocrine form of intercellular
communication of NRG. In the paracrine form, the soluble NRG produced by 293 cells activates the HER receptors on MCF7 cells that
reside at a certain distance from where the NRG is synthesized. In the juxtacrine form, the transmembrane NRG produced in MCF7 cells is
able to active the HER receptors present at the membrane of cells that are in physical contact with the cell that produces the NRG. In the
autocrine form, the soluble NRG produced in MCF7 cells is able to active HER receptors in the same cell that produced the NRG. (B) Effect
of the conditioned medium of 293, 293-NRGa2c, and 293-NRGDIg cells in proliferation. MCF7 cells were stimulated with the indicated
conditioned medium, and MTT metabolization was measured 5 days later. ***P < 0.001. (C) Expression of proNRGa2c and proNRGDIg in
MCF7tetoff cells. Clones of MCF7tetoff expressing proNRGa2c and proNRGDIg (MCF7-NRGa2c and MCF7-NRGDIg) were cultured with or
without doxycycline (DOX, 10 ngmL1) during 2 days and then lysed. The samples were analyzed by western blotting with the anti-
endodomain antibody. (D) The levels of sNRG released in the conditioned medium of MCF7-NRGa2c and MCF7-NRGDIg cells were analyzed
by western blotting with the anti-ectodomain antibody. (E) Subcellular distribution of proNRGa2c and proNRGDIg in MCF7 cells was analyzed
by immunofluorescence using the anti-endodomain antibody. Nuclear staining was performed with DAPI. Images were captured using a
Leica TCS SP5 confocal microscope. Bar, 25 lm. (F) Protease protection experiments. Intact MCF7tetoff cells expressing proNRGa2c and
proNRGDIg were treated with or without proteinase K and lysed. The samples were analyzed by western blotting with the anti-endodomain
antibody. (G) Proliferation of MCF7, MCF7-NRGa2c, and MCF7-NRGDIg cells. These cells were cultured in the presence or absence of
doxycycline (10 ngmL1), and MTT metabolization was measured 5 days later. ***P < 0.001. (H) Cells cultured in the presence or absence
of doxycycline (10 ngmL1) were treated with or without NRG 10 nM, and the MTT metabolization was measured 5 days later.
***P < 0.001.
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cell proliferation found between the cell lines were not
due to differences in their proliferative capabilities.
3.6. HER pathway activation in MCF7-NRGa2c
and MCF7-NRGDIg cells and sensitivity to
trastuzumab
The signaling capability of wild-type proNRGa2c and
proNRGDIg in MCF7 cells expressing these forms was
then analyzed. Resting levels of pHER2, pHER3,
pAKT, and pS6 were higher in MCF7-NRGa2c than
in MCF7-NRGDIg cells (Fig. 5A,B). Repression of
NRG expression by the addition of doxycycline
reduced the phosphorylation status of all these pro-
teins, especially in MCF7-NRGa2c cells. Both cell
lines responded to the addition of exogenous NRG,
indicating that they preserved signaling responses to
the added growth factor.
The sensitivity of MCF7-NRGa2c and MCF7-
NRGDIg cells to the anti-HER2 therapeutic antibody
trastuzumab was then explored. Trastuzumab has been
formerly reported to exert a potent inhibition of prolif-
eration of NRG-expressing cells (Yuste et al., 2005).
Moreover, clinical responses to trastuzumab have been
shown to correlate with the expression of NRGs in
breast cancer tumors which do not overexpress HER2
(de Alava et al., 2007). Trastuzumab substantially
decreased proliferation of MCF7-NRGa2c cells
(Fig. 6A). Such decrease in cell proliferation was at
least the magnitude obtained by repressing the expres-
sion of proNRGa2c by treatment with doxycycline.
Combination of trastuzumab treatment with repression
of the expression of proNRGa2c did not augment the
inhibition of cell proliferation caused by trastuzumab
alone. These data indicated that trastuzumab neutral-
ized the proliferation advantage supplied by the
expression of proNRGa2c in MCF7 cells.
Trastuzumab slightly decreased the proliferation of
MCF7-NRGDIg cells. Addition of doxycycline or com-
bination of the latter with trastuzumab did not sub-
stantially change the proliferation of these cells when
compared to that of untreated MCF7-NRGDIg cells.
Western blotting (Fig. 6B) and quantitative analyses
(Fig. 6C) demonstrated that trastuzumab inhibited the
degree of constitutive activation of HER3, and AKT
present in MCF-NRGa2c cells. Interestingly, the levels
of pHER2 were poorly affected by trastuzumab in
MCF7-NRGa2c cells. Trastuzumab also decreased
HER2 IP: HER2
WB: HER2
– + – + – + – +
– – + + – – + +
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Fig. 5. Cell surface NRGa2c activates signaling through ErbB receptors. (A) MCF7-NRGa2c and MCF7-NRGDIg cells cultured in the presence
or absence of doxycycline (10 ngmL1) and treated with or without NRG (10 nM) during 15 min were lysed. Immunoprecipitation (where
pertinent) and western blotting were performed with the indicated antibodies. (B) Graphical representation of the quantification of the
phosphorylation of HER2, HER3, AKT, and S6. Data are expressed as the mean  SD of two independent experiments, except for the
phosphorylation of S6, performed as in B.
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pHER3 levels in MCF7-NRGDIg cells. However, an
action of trastuzumab on the activation status of the
other proteins analyzed (pHER2 and pAKT) could not
be adequately interpreted as their degree of activation
was very low in MCF7-NRGDIg cells (Fig. 6B,C). The
levels of pERK1/2 were low in both cell lines and were
not affected by trastuzumab or doxycycline. We also
tested the action of pertuzumab, an antibody that inhi-
bits ligand-dependent HER2 receptor dimerization
(Agus et al., 2002), on pHER2, pHER3, and
downstream signaling. These experiments reported simi-
lar results to those obtained with trastuzumab (Fig. S1).
However, it should be noted that pertuzumab decreased
pHER2 levels in MCF7-NRGa2c cells.
4. Discussion
The accumulation of reports that link NRGs to cancer
justifies studies aimed at deciphering the relevance of

































































































































Fig. 6. MCF7-NRGa2c cells are sensitive
to the anti-HER2 therapeutic antibody
trastuzumab. (A) Effect of trastuzumab in
the proliferation of MCF7-NRGa2c and
MCF7-NRGDIg. Cells cultured in the
presence or absence of doxycycline
(10 ngmL1) were treated with or
without trastuzumab (50 nM), and the
number of the cells was counted 5 days
later. ***P < 0.001. (B) MCF7-NRGa2c
and MCF7-NRGDIg cells cultured in the
presence or absence of doxycycline
(10 ngmL1) and treated with or without
trastuzumab (50 nM) and NRG (10 nM)
during 15 min. The cells were lysed and
the expression of different proteins was
analyzed by western blotting with the
indicated antibodies. (C) Graphical
representation of the quantification of the
phosphorylation of HER2 and HER3. Data
are expressed as the mean  SD of
three independent experiments performed
as in B.
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not only because of that, but also because such studies
may uncover new therapeutic possibilities. In fact,
some reports have already approached that latter pos-
sibility, showing the therapeutic benefit of acting on
the NRG-ErbB system (Jones et al., 2017). While
some studies have offered information on the role of
different domains in the sorting of NRGs (Montero
et al., 2007, 2011), the impact of elimination of the dif-
ferent domains on their biological activity has not
been explored and had to be done. With that purpose
in mind, we prepared several deletion mutants of
proNRGa2c, a prototypical proNRG, and analyzed
their biological activity, measured as capability to acti-
vate HER receptors and proliferation responses.
We observed that the Ig-like domain of proNRGs
exerts an important role in their signal-promotion capa-
bilities, but did not affect cell surface sorting. In fact,
elimination of the Ig-like region did not affect transport
and accumulation of the mutant proNRGDIg at the cell
surface, as indicated by immunofluorescence or pro-
teinase K protection experiments. Moreover, regulated
proteolytic cleavage, which exclusively occurs at the cell
surface (Montero et al., 2007), was unaffected by dele-
tion of the Ig-like domain, not only indicating that such
domain is dispensable for proteolytic cleavage, but also
supporting the fact that proNRGDIg reached the cell
surface as well as wild-type proNRGa2c. That such
cleavage occurred similarly to that of the wild-type pro-
tein was also suggested by the accumulation of sNRGDIg
in the culture media, in amounts similar to those
observed in the media of proNRGa2c-expressing cells.
Initially surprising was the fact that conditioned
media from 293 cells expressing proNRGDIg were much
less efficient in promoting tyrosine phosphorylation of
HER receptors. Such effect was accompanied by
decreased phosphorylation of several proteins that are
used as readouts of activation of pathways that partici-
pate in NRG–HER signal transduction. As a final con-
sequence, the much lower activation of signaling by this
system translated into poor stimulation of cell prolifera-
tion by NRGDIg with respect to wild-type NRGa2c.
The reason for the failure of soluble or transmem-
brane NRGDIg to efficiently activate HER2 and HER3
is unknown. Former reports indicated that the Ig-like
domain is required for efficient interaction of the EGF-
like domain of NRGs with their receptors (Eto et al.,
2006). Such phenomenon can be due to a direct action
of the Ig-like region of NRGs on receptor binding or a
more global change in the structure affecting the EGF-
like region, and ultimately altering interaction with
HER receptors. While this appears possible, it is worth
mentioning that other growth factors that belong to the
EGF family of transmembrane growth factors, such as
proTGFa, are devoid of Ig-like domains and their sol-
uble form is biologically active (Massague and Pan-
diella, 1993). It is also interesting to mention that most
commercially available forms of NRGs are prepared
without the Ig-like domain and are active. It is possible
that the amounts used are much higher than the
amounts we used from the culture media and that may
explain the weak stimulation properties of the media
form proNRGDIg-transfected cells as compared to the
wild-type or even to the commercially available NRG.
Using the MCF7 reporter system, we observed that
activation of HER3, measured as its tyrosine phospho-
rylation, was more efficiently induced by sNRGa2c with
respect to sNRGDIg. Such differential action may be due
to several circumstances. Tyrosine phosphorylation of
HER receptors has been shown to occur in an asymmet-
ric manner, in which a donor receptor phosphorylates
tyrosine residues of an adjacent acceptor receptor
(Zhang et al., 2006). In the case of HER2–HER3 recep-
tor dimers, and due to the deficient kinase activity of
HER3 (Shi et al., 2010), the latter is expected to mainly
act as the acceptor receptor, being HER2 the donor
kinase. The restricted kinase activity of HER3 may very
well explain the poor tyrosine phosphorylation of
HER2, as indicated by western blotting experiments
with anti-HER2 phosphospecific antibodies. Moreover,
previously published results (Sanchez-Martin and Pan-
diella, 2012) have already shown that the pY signal
obtained in western blots in which HER2 was immuno-
precipitated after stimulation with NRG could be due
to pY-HER3 which coprecipitated with HER2.
As proliferation of MCF7 cells has been reported to
be insensitive to the action of trastuzumab (Agus
et al., 2002; Yuste et al., 2005), it is interesting that
this drug had an effect on the proliferation of MCF7-
NRGa2c cells. While such finding has already been
reported (Yuste et al., 2005), the responsible mecha-
nism of action was not explored. Interestingly, the
amount of pHER2 present in MCF7-NRGa2c cells
was poorly affected by trastuzumab, a finding that
falls in line with published data using soluble NRG to
activate HER2 (Agus et al., 2002). In contrast, trastu-
zumab has a substantial effect on the tyrosine phos-
phorylation of HER3, and on the activation status of
AKT. Those findings are relevant, given the important
role of the HER3–PI3K signaling route in the prolifer-
ation of breast cancer cells (Chakrabarty et al., 2012).
Our results, together with data available in the litera-
ture, led us to postulate that the antiproliferative
action of trastuzumab on MCF7-NRGa2c cells may
occur indirectly, by decreasing the HER2-mediated
tyrosine phosphorylation of HER3, which in turn
affects HER3-dependent downstream signaling.
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An important aspect that requires some comments is
to which extent the results herewith reported may have
a translational impact. The finding that the Ig-like
domain of proNRGs favors their HER receptor activat-
ing properties opens the possibility of targeting that
domain to improve the effectiveness of anti-NRG thera-
pies. Due to the unquestionable capability of NRGs to
promote proliferation of cells bearing HER receptors,
neutralization of NRG activity may represent an attrac-
tive approach (Jones et al., 2017; Montero et al., 2007,
2011; Yuste et al., 2005). One could envisage several
scenarios in which neutralization of NRGs may be of
potential therapeutic benefit. On the one hand, neutral-
izing anti-NRG antibodies may reduce proliferation of
tumors in which NRGs fed tumoral cells expressing
HER receptors. Moreover, the expression of NRGs by
some tumoral tissues may offer additional novel thera-
peutic possibilities, some of them based on their struc-
tural and cell biological properties. Thus, the fact that
NRGs are synthesized as transmembrane molecules
offers the possibility of raising antibodies that recognize
the extracellular region of the proNRGs. These antibod-
ies may not only neutralize the growth-promoting prop-
erties of NRGs, but may also serve to generate immune
responses against the tumor, similarly to those raised
against therapies that target the HER receptors (Clynes
et al., 2000). Furthermore, considering the transmem-
brane nature of proNRGs, they could preserve proper-
ties similar to those of other transmembrane proteins,
such as HER receptors, including internalization and
recycling (Sorkin and Goh, 2009). Given the fact that
some efficient treatments directed to those receptors
include antibody–drug conjugates that internalize and
deliver a cytotoxic drug, the possibility of using a similar
approach to target tumoral cells expressing proNRGs
appears attractive and should be explored.
5. Conclusion
In conclusion, this report demonstrates that the Ig-like
region of proNRGs exerts an important role in their
capability to activate mitogenic responses upon ErbB/
HER receptor activation. This knowledge is important
when considering the potential targeting of proNRGs
in tumors, as it may improve the antiproliferative
properties of agents aimed at neutralizing the pro-
oncogenic properties of proNRGs.
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